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Abstract.  Liquid array technology has previously been used to show proof-of-principle of a 
multiplexed non structural protein serological assay to differentiate foot-and-mouth infected and 
vaccinated animals.  The current multiplexed assay consists of synthetically produced peptide 
signatures 3A, 3B and 3D and recombinant protein signature 3ABC in combination with four 
controls.  To determine diagnostic specificity of each signature in the multiplex, the assay was 
evaluated against a naïve population (n = 104) and a vaccinated population (n = 94).  
Subsequently, the multiplexed assay was assessed using a panel of bovine sera generated by the 
World Reference Laboratory for foot-and-mouth disease in Pirbright, UK.  This sera panel has 
been used to assess the performance of other singleplex ELISA-based non-structural protein 
antibody assays.  The 3ABC signature in the multiplexed assay showed comparative 
performance to a commercially available non-structural protein 3ABC ELISA (Cedi test®) and 
additional information pertaining to the relative diagnostic sensitivity of each signature in the 
multiplex is acquired in one experiment.  The encouraging results of the evaluation of the 
multiplexed assay against a panel of diagnostically relevant samples promotes further assay 
development and optimization to generate an assay for routine use in foot-and-mouth disease 
surveillance.   
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Liquid array technology allows simultaneous measurement of the relative responses of 
multiple signatures to a challenge sample (19).  This technology has proven successful for 
multiple applications; antigen and nucleic acid-based biological threat agent detection (27, 28) 
and serological assays (3, 16, 20, 23, 35, 42, 43) are a few examples.  The use of such 
multiplexing technology has time, cost and manpower benefits over multiple, singleplex 
analyses, in addition to an increased confidence in results.  Multiple signature evaluation 
provides more confidence when obtaining a conclusive result, it eliminates variations that may 
occur when using a series of singleplex assays to obtain a comparative result, and it allows 
controls in every sample.  The liquid array consists of beads that are embedded with precise 
ratios of red and infrared fluorescent dyes yielding 100-bead sets, each with a unique spectral 
address.  Analyte that is captured on a modified bead is detected using a detector reagent, 
indirectly labeled with a fluorescent reporter.  Each optically encoded and fluorescently labeled 
bead is then interrogated by a flow cytometer.  A classification laser (635 nm) excites the dye 
molecules inside the bead and classifies the bead to its unique bead set.  A reporter laser (532 
nm) excites the bound fluorescent reporter and quantifies the assay at the bead surface.  The flow 
cytometer is capable of reading around one hundred beads per second; analysis can be completed 
in as little as 15 s and potentially up to 100 different analytes can be assayed simultaneously, 
thereby providing a high-throughput and economic platform. 
Foot-and-mouth disease (FMD) is a highly infectious and contagious vesicular disease 
affecting cloven-hoofed animals.  Foot-and-mouth disease virus (FMDV) belongs to the genus 
Aphthovirus in the Picornaviridae family and includes seven serotypes; O, A, Asia, C, SAT1, 2 
and 3.  The circulation of foot-and-mouth disease virus (FMDV) in an animal population imparts 
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severe restrictions on the movement of animal products, and consequently, the international trade 
of the affected region.  FMD is endemic in many parts of Asia, Africa and South America.  
Moreover, the disease periodically breaks out in FMD-free countries (7) and in either case, can 
have a significant economic impact on the affected region.  An outbreak of FMD can be 
controlled by culling infected and contact susceptible animals or by the use of emergency ring 
vaccination, a so-called vaccinate-to-live policy.  Vaccination is used in South America (6) as 
part of a continent-wide effort to eradicate the endemic disease (5).  However, FMD vaccines do 
not provide sterile immunity and animals can become clinically or sub-clinically infected and 
ultimately become a carrier of the virus, which is considered as a threat of spreading disease to 
other susceptible animals (13-15, 17, 22, 30).  Therefore, to regain FMD-free status and re-
enable international trade, post-vaccinal surveillance is required to demonstrate the absence of 
persistent infection in a vaccinated population (1).   
Both infection and vaccination elicit antibodies against structural antigens as FMD 
vaccines are chemically inactivated, semi-purified virions.  Therefore, only assays that measure 
levels of antibodies against non-structural protein (nsp) can differentiate infected and vaccinated 
animals (DIVA) providing the vaccine used is of high purity (40).  Researchers have reported 
many assays capable of detecting antibodies against FMDV nsps (8, 9, 18, 25, 34, 45, 47, 49).  
All of the reported single signature assays are based on the ELISA plate format.  Vaccine / 
challenge experiments have recently been used to evaluate the performance of nsp antibody 
assays (13, 14, 31, 38) and these studies showed that a single nsp assay could not always detect 
persistent infection to declare absolute freedom of infection in vaccinated herds.  Indeed, 
Bergmann and coworkers at the Pan American FMD Center in Rio de Janeiro, Brazil have 
implemented a combination of a 3ABC ELISA and an enzyme-linked immunoelectrotransfer 
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blot assay to gain high specificity and sensitivity in FMDV serological monitoring in South 
America (5, 6).  An international workshop for the validation of nsp tests in Brescia, Italy (8, 40) 
proposed the use of at least two assays to attain ideal sensitivity and specificity.  This is 
consistent with the theory of liquid array, multiplexing technology allowing simultaneous 
multiple signature evaluation, providing more confidence in obtaining a conclusive result and 
has previously been shown to be a promising platform for the development of a multiplexed nsp 
FMD DIVA assay (11, 41).  Here, further development and evaluation of the multiplexed nsp 
antibody assay is described using samples originating from two vaccine / challenge experiments 
and a panel of bovine serum samples assembled to the test relative sensitivity of nsp antibody 
assays.  The sera panel consists of samples originating from various vaccine potency experiments 
conducted at the World Reference Laboratory (WRL) for FMD in Pirbright, UK and covers four 
different serotypes (O, A, Asia1 and SAT2) (38). 
  
Materials and Methods. 
Multiplexed reagent preparation and assay procedures have been previously described in 
detail (41).  Therefore, reagent preparation and assay protocols are outlined briefly except in the 
case of updated specifics, where a full description is reported. 
General. All reagent dilutions and assays were carried out in PBS-TN (phosphate 
buffered saline, pH 7.4; Tween 20 0.02 % v/v; sodium azide 0.02 % w/v) and filtered through 
Corning 0.22 µm filter systems before use. 
Bead mixture.  The bead mixture consisted of 8 beads sets – 4 assay beads and 4 controls 
(28).  Synthetically produced (United Biochemical Research, Seattle, WA) peptides 3A, 3B and 
3D (peptide sequences described previously) and gel purified recombinant nsp 3ABC (12) were 
 4
each covalently coupled to a unique carboxylate bead class (Luminex Corp.) using the 
carbodiimide activation as described previously.  Peptide / protein solutions were at 1.7 µM for 
bead coating.  Control beads were coated as described previously and consisted of an instrument 
control (IC), fluorescent control (FC), antibody control (AC) and a negative control (NC).  Bead 
mixture was formulated in PBS-TN to a theoretical final concentration of ~ 5.4 x 10
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6 of each 
bead class / mL.  This gives a 10X mixture that can be stored over time.  Following formulation, 
the bead mixture was enumerated by taking 5 µL of the 10X bead mixture, diluting it in 95 µL 
PBS-TN and counting all the beads in a 50 µL sample using a Bio-Plex system (Bio-Rad).  If the 
bead count of a particular class was significantly (> 30%) lower than the others, a compensatory 
amount of that bead was added to the bead mixture.  With this dilution and enumeration method, 
the numbers of bead in each class was approximately 500.  The bead mixtures were stored at 4 
ºC in the dark and diluted 10-fold directly before use. 
Detector reagent.  The detector (secondary) antibody cocktail was prepared as a mixture 
of biotin-SP-conjugated Affinipure Goat anti-bovine (Jackson ImmunoResearch Laboratories) at 
30 µg / mL and biotin-SP conjugated Affinipure rabbit anti-chicken IgY (IgG), Fc fragment 
specific (Jackson ImmunoResearch Laboratories) as a control at 0.2 µg / mL in PBS-TN and 
diluted 10-fold directly before use. 
Reporter reagent. Streptavidin-R-phycoerythrin (SA-PE) (Caltag Laboratories) was 
prepared in PBS-TN at 24 µg / mL and diluted 10-fold in PBS-TN directly before use for a 
working concentration of 2.4 µg / mL. 
Serum sample preparation for multiplexed assays.  All serum samples were stored at – 20 
ºC.  Samples were thawed and diluted 1:400 for serial bleed assays in PBS-TN directly before 
use.  All samples were used in an assay a maximum of 1 h post dilution.   
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Sera  — General.  The sera were collected during the course of a series of vaccination / 
challenge experiments carried out in biosecurity containment at the WRL for FMD, Pirbright, 
UK.  Typically, naïve cattle were vaccinated, and at 21 days post vaccination (dpv), were 
challenged by either homologous or semiheterologous FMD virus by intradermolingual 
inoculation or by direct contact with infected cattle.  Sera were collected at various days pre- 
(dpv) and post-challenge (dpc).  The experimental details, including virological and serological 
findings, have been extensively reported (13, 14, 36-39).  The experiments were designated with 
a two letter identifier (e.g. UV) and these identifiers coupled with a number are used to describe 
each animal in an experiment.   
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Sera from naïve cattle.  104 serum samples were collected from cattle at the beginning of 
vaccination / challenge experiments before any administration of vaccine or virus.  The 
identifications of the samples are listed in the supplemental material.   
Sera from vaccinated and infected cattle.  94 serum samples were tested from cattle at 14 
or 21 dpv, in some cases from the same animal at the different time point, during the course of 
vaccination / challenge experiments.  The identification and dpv of the vaccinated samples are 
listed in the supplemental material.  In addition, samples from two O serotype vaccine / 
challenge experiments (UV (14) and UY series (13)) were tested at 0 dpv, 14 dpv, 21 dpv/0 dpc 
and 28 dpc.  The details of the experiments used to generate these samples has been previously 
reported in full. 
Bovine sera panel.  36 bovine serum samples were selected from a series of vaccination / 
challenge experiments.  The details of the experiments used to generate these samples has been 
previously reported in full (13, 14, 37, 38).  The state of the animal (vaccination, challenge, 
mode and serotype of challenge, and carrier status etc.) when the serum samples were taken is 
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summarized in Table 1.  The bovine sera panel was also tested after heat-inactivation at 56 °C for 
2 h. 
Assays.  A 96-well MultiScreen-BV 1.2 µm filter plate (Millipore) was wetted with 100 
µL PBS-TN.  100 µL of diluted sample was deposited in each well.  50 µL bead mixture to each 
sample well and incubated in the dark for 20 min.  Samples were washed twice with 100 µL 
PBS-TN.  The beads were re-suspended in 100 µL PBS-TN, 50 µL detector reagent was added 
and incubated in the dark for 15 min.  Samples were washed with 100 µL PBS-TN.  The beads 
were re-suspended in 100 µL PBS-TN, 50 µL SA-PE was added, and incubated in the dark for 5 
min. The samples were washed with PBS-TN and re-suspended in 100 µL PBS-TN.  Finally, the 
suspended beads were transferred to a Corning Costar round-bottomed 96-well plate for analysis 
with a Bio-Plex configured to count a minimum of 100 beads per class and a 50 µL sample size.  
Normal bovine serum (Sigma) and a strong positive sample (UV23, 37 dpc) were used on each 
plate as a negative and positive control respectively, at 1:400 dilution in PBS-TN. 
 
Results. 
Liquid array technology has been used to develop a multiplexed nsp-based DIVA assay 
for FMD (41).  Figure 1 shows a schematic representation of the liquid array bead-based nsp 
assay.  Each antigen is covalently conjugated to a particular bead set.  The covalently bound 
antigen captures antibodies in sera from FMDV-infected animals.  A biotinylated secondary or 
detector antibody and streptavidin-phycoerythrin reporter quantify the assay at each bead surface 
as the complex is analyzed in a flow cytometer.  Previous work showed a close correlation 
between the response of recombinant nsps and synthetically produced peptides 3A, 3B and 3D 
on this platform (41).  Therefore, three peptides representing nsp antigens 3A, 3B and 3D were 
 7
155 
156 
157 
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
172 
173 
174 
175 
176 
177 
combined with recombinant nsp antigen 3ABC and four controls—an instrument control (IC), a 
fluorescent control (FC), an antibody control (AC) and a negative control (NC)—to generate an 
8-plex for further development.  Peptides were chosen over recombinant antigens where 
appropriate as peptides can be easily produced in large quantities under strict QC control without 
biosafety level 3 containment.  Recombinant antigen 3ABC remained in the multiplex as this 
signature is commonly used in ELISA nsp assays (2, 4, 6, 8-10, 24, 29, 33, 38, 44, 46).   
The 8-plex assay was tested against 104 FMD-naïve serum samples to establish normal 
variation in a naïve population and also to determine a cut off, above which a sample is deemed 
positive for infection with FMDV.  During initial development of the multiplexed assay, the 
response on the antigen-coated or “assay” beads during the first few days of infection was 
extremely low and the response on the BSA-coated NC bead remained more or less constant 
when analyzing samples from serial bleeds of experimentally infected cattle (41).  However, 
upon expanded analysis of samples from a naïve population of cattle (data not published to date), 
significant differences in the responses of the assay beads were observed.  This correlated with 
large differences in the response of the NC bead.  Therefore, the NC is used to normalize the 
response of the assay beads and other researchers have used this approach to normalize liquid 
array-based serology assay results (21).  Significantly, FMDV-infected cattle generally maintain 
a low response on the NC and therefore, normalization effectively increases the sensitivity of the 
multiplexed liquid array assay. 
Figure 2a-d shows the normalized response on each of the four assay beads in response to 
sera from 104 FMD naïve cattle.  The animal identification codes, the crude median fluorescence 
intensity (MFI) values on all beads including controls, the normalized values and standard 
deviations are listed in the supplementary material.  The standard deviation on the normalized 
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responses of the naïve population was on average ~10 % of the value.  The 104 samples were 
used to generate a cut off of 97 % specificity for antigens 3A, 3D and 3ABC and 95 % for 3B.  
Positive bars in Figures 2a-d are above cut off.  Sera from 94 vaccinated cattle were also run 
against the multiplexed assay and the normalized responses of each assay bead to each sample 
are shown in Figure 3a-d.  The samples were taken from cattle 14 dpv (black bars) and 21 dpv 
(gray bars).  The animal identification codes, the crude MFI values on all beads including 
controls, the normalized values and standard deviations are listed in the supplementary material.  
The standard deviation on the normalized responses of the naïve population was, on average, ~10 
% of the value.  Using the cuts offs determined from the naïve populations (positive bars are 
above cut off in Figure 3) antigen 3A showed a specificity of 96 %, antigen 3B 97 %, antigen 3D 
93 % and 3ABC 97 % indicating a vaccinated population gives a similar response to a naïve 
population provided the vaccine used is of high purity. 
The multiplexed assay was used to analyze the 36 samples of a bovine sera panel 
assembled by the WRL for FMD (38).  Table 1 lists the origin of each sample including the 
details of vaccination and challenge and the time at which the sera were collected.  The 
normalized responses of each antigen in the multiplex to each sample are listed in Table 2.  The 
data in Table 2 are an average of two experiments, three repeats for each sample in each 
experiment.  The crude MFI values on all beads including controls, the normalized values and 
standard deviations are listed in the supplementary material.  The serum samples are divided into 
groups depending on vaccination / carrier status in accordance with previously published 
material (13, 14, 36, 37).  In addition, the qualitative results obtained when using the Cedi® test 
(Cedi Diagnostics, Lelystad, The Netherlands), a 3ABC ELISA, are listed as a comparison.  The 
results of the Cedi® test and other non-structural antibody assay results for each sample in the 
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panel have been previously reported (38).  The cut off for each antigen generated from the naïve 
population was applied to the results obtained for bovine serum panel.  The 3ABC antigen in the 
multiplexed assay shows good correlation with the Cedi® test results with the exception of 
sample UV83, which proved negative with the multiplexed assay.  However, two carrier cattle 
(UZ59 and UZ62, carrier status confirmed by RT-PCR / virus isolation) were also detected 
positive by the 3A, 3B and 3ABC signature in the multiplexed assay, whereas they were missed 
by the Cedi® test.  Moreover, vaccinated, non-carrier animal UZ54 was clearly positive 
according to the multiplexed assay, but gave positive and negative results in the Cedi® test.  The 
other signatures, 3A, 3B and particularly 3D showed a large range in responses to each sample 
and the values depended heavily on the serotype of the vaccination / challenge and the time point 
at which the serum sample was taken.  The significance of these differences is discussed more 
fully below. 
Table 3 shows the response of the multiplexed assay when run against the heat-
inactivated serum panel to determine if heat inactivation affected the results of the multiplexed 
assay.  The crude MFI values on all beads including controls, the normalized values and standard 
deviations are listed in the supplementary material.  Heat inactivation reduces the likelihood that 
the serum samples are contaminated with live FMDV and allows the samples to be analyzed 
outside BSL-3 containment.  Therefore, it is important to determine if the performance of nsp 
antibody assays are not adversely affected by heat inactivation of the sera.  Heat inactivation of 
the serum samples generally lowered the response obtained on each antigen, but only in a few 
cases the response fell below the cut off, changing the status of the sample. 
Tables 4 and 5 show the results from the analysis of four samples from each of 25 cattle 
in two vaccination / challenge experiments (13, 14) and compare the results of the multiplexed 
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assay with the previously reported results of the Cedi® test for the samples 28 dpc.  The serum 
samples were taken at 0 dpv, 14 dpv, 21 dpv/0 dpc, 28 dpc.  Again, the cattle are grouped 
according to their serological status, which has previously been determined.  Table 4 shows 
results of the herd of cattle following vaccination with O
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1 Manisa oil adjuvant vaccine and 
challenge by direct contact with O UKG 34/2001.  Generally, the vaccinated, non-carrier cattle 
are negative for antibodies to nsps pre- and post-challenge with a few exceptions.  UV15 (3A 
and 3ABC) and UV20 (3ABC) rose above cut off post challenge and this is contrary to the 
results of the Cedi® test.  UV6 and UV7 are false positives on one signature 0 dpv.  UV12 
shows a large degree of non-specific binding, particularly on 3A, throughout the experiment.  
There is a good correlation between the results obtained with the 3ABC signature in the 
multiplexed assay and the Cedi® test on the samples from vaccinated, carrier cattle 28 dpc and 
again, the other antigens in the multiplex show different degrees of response.  The unvaccinated 
control cattle 28 dpc show large responses against all antigens in the multiplex, with the 
exception of the 3D antigen with sample UV25.  Table 5 shows the results of a herd of cattle 
following vaccination with a high potency dose of O1 Manisa vaccine, resulting in fewer cattle 
with a carrier status.  Again, there is good correlation in the results obtained against samples 
taken 28 dpc with the 3ABC antigen in the multiplex and the results of the Cedi® test with the 
exception of UY79.  Samples UY77 and UY87 have large false positive results on the 3D 
signature on samples pre-challenge.  Sample UY81 also shows false positive results on the 
3ABC signature pre-challenge.  The unvaccinated control cattle 28 dpc show large responses 
against all antigens in the multiplex, with the exception of the 3D signature with UY94, UY96 
and UY97. 
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When assessing the performance of a novel assay platform or signatures, it is essential to 
compare performance with standard samples against a current ‘gold standard’ assay.  To 
compare relative sensitivities of nsp antibody assays, the World Reference Laboratory (WRL) 
for FMD in Pirbright, UK generated a bovine sera panel comprised of thirty-six samples (38).  
The sera panel was carefully selected to test relative assay sensitivity and reagent batch-to-batch 
reproducibility and contains diagnostically significant samples from vaccination / challenge 
experiments in addition to sera from directly infected cattle as strong positives.  The panel also 
contains sera from cattle defined as carriers and from cattle 3–5 months post challenge.  
Significantly, the panel contains samples from cattle infected by contact, mimicking the mode of 
infection in the case of an outbreak.   
 Previously, the multiplexed assay was carried out using PBS, Tween 20, BSA and 
sodium azide (41) as an assay buffer.  However, during the initial course of the experiments 
reported here, the product number and type of BSA appeared to have an effect on the assay, 
severely reducing binding to the beads.  Therefore, to eliminate the possibility of end users 
inadvertently using different vendors for BSA in the assay buffer and consequently achieving 
anomalous results, BSA was removed from the assay buffer in this further development. 
Samples from FMD naïve cattle were used to generate a cut off for each signature in the 
multiplexed assay.  Figure 2 shows the responses of each signature to this naïve population.  The 
cut off was determined individually for each signature to give high specificity; 97 % for 3A, 3D 
and 3ABC, 95 % for 3B.  Signatures 3A and 3ABC gave the lowest values on the false positives 
and 3D showed the largest variation in response in a naïve population.  It appears there is a large 
degree of non-specific binding on the 3D signature in naïve sera and this variation increases the 
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cut off of the 3D signature.  The false positives on the 3D signature were also large responses.  
The responses of the vaccinated population shown in Figure 3 are very similar to the naïve 
population with similar specificities on each signature.  It should be noted that the vaccines used 
to vaccinate this population were inactivated virus of high purity and not contaminated with nsps 
and therefore, these samples were expected to have a similar response to a naïve population.   
Against the sera panel (Table 2), the 3ABC signature in the multiplex showed 
comparable performance to the Cedi® test, a 3ABC ELISA, where all samples except UY83 
exhibited a positive response, i.e. equal to or above cut off.  Peptide signatures 3A and 3B 
peptide signatures exhibited a positive response to many of the samples, the exceptions being in 
the UV and UY series samples at 3-5 months post challenge.  It should be noted that the 3ABC 
protein signature contains both the 3A and 3B epitopes, and the individual assessment of the 3A 
and 3B in the multiplexed assay reports the relative response of each epitope.  The 3D signature 
generally performed poorly against weak positive samples the panel.  The responses were ‘all or 
nothing’, giving a large positive response to some samples, and a very negative response to 
others.  The 3D signature is a peptide representing the immunogenic amino-terminus of the 
whole 3D nsp and the 3D protein is regarded as the most immunogenic of the nsps.  
Furthermore, the 3D signature alone is not considered a DIVA marker, as nsp 3D has been 
shown to be a contaminant in vaccine formulations that may be due to the presence of one copy 
of the 3D polymerase enzyme in the virion (32) and consequently, it is possible for vaccinated 
animals to raise antibodies against the 3D signature (26, 47).  However, simultaneous multiple 
signature evaluation allows the consideration of the response of the 3D signature in the context 
of the responses of the other signatures to give increased confidence in calling a result.  Further 
investigation of the performance of the 3D peptide signature is included in future development.  
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The large dynamic range of the responses in the multiplexed assay is also of note.  Normalized 
responses range from just above cut off for the samples expected to have low levels of antibodies 
i.e. 3-5 months post challenge to 20-30 times cut off for strong positives.  The liquid array 
technology with fluorescent detection is extremely sensitive considering the serum samples are at 
a final dilution of 1:600 in the assay.  This dilution factor is required for the bead-based serology 
assay; with significantly lower dilution factors, the non-specific binding on the antigen-coated 
beads overwhelms the specific interaction.  There have been attempts to reduce the non-specific 
binding in liquid array serology assays (48), including the production of commercially available 
serology beads (Luminex Corp), however it remains a challenge to reduce background in bead-
based serological assays. 
While heat-inactivation of the serum samples generally lowered the responses of each 
signature (Table 3), it only changed the final results of a few signatures on a few samples.  In 
addition, this analysis was using a cut off determined from the analysis on untreated sera.  It is 
likely that the cut offs generated from the analysis of heat-treated naïve sera would also be lower, 
and therefore, heat-inactivation has little overall effect on the performance of the liquid array 
multiplexed assay.   
The overall results of the O Manisa vaccination / O UKG challenge (UV and UY series) 
experiments have been previously reported (13, 14).  The analysis of the samples with the 
multiplexed assay again allowed comparison with the results of the Cedi® test.  In general, the 
results of the 3ABC signature in the multiplexed assay correlated with the results of the Cedi® 
test and the results on signatures 3A, 3B and 3D were variable.  Once again, a large dynamic 
range is observed.  The results from the analysis of samples from unvaccinated, control cattle 
show much larger response on all signatures than the vaccinated carrier cattle correlating with 
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observations in many singleplex nsp ELISA experiments (37).  This may be attributed to the 
limited replication of FMDV in vaccinated animals where the levels of neutralizing antibodies 
are significantly higher than in unvaccinated animals.  A few samples from vaccinated, non-
carrier cattle show some non-specific binding in various time points in the experiment.  
Including the responses of cattle at 28 dpc shows the responses at the beginning of the time 
frame that is particularly significant when using serological surveillance for FMDV post 
outbreak.  Future experiments will include analysis of these samples 1-3 months post challenge 
as this is the time period that sero-surveillance would take place post-outbreak to declare a 
disease-free status. 
In conclusion, the liquid array, multiplexed nsp antibody assay shows good performance 
against a panel of sera designed to assess the relative sensitivity of nsp antibody assays with 
diagnostically relevant samples.  The 3ABC signature in the multiplex shows comparable 
performance to a widely used commercially available assay, and in addition, the multiplexed 
assay provides a large amount of extra information about the relative diagnostic sensitivity of 
each signature in one experiment.  This feature of the multiplexed assay is particularly attractive 
when considering the potential use of the assay in vaccine development and assessing vaccine 
purity.  It is trivial to prepare antigen-coated beads for serological applications, once capture 
agents have been generated and the assay is completed in 1 h.  The multiplexed assay is rapid, 
conducive to automation and a crude cost evaluation of reagents and consumables comes to US 
50 c per assay, which is not cost-prohibitive.  Following this encouraging evaluation of the 
sensitivity and specificity of the multiplexed assay, experiments to evaluate field performance, 
stability of reagents and reagent lot-to-lot repeatability and possibly expanding the multiplex to 
cover all FMDV nsp signatures will be carried out.  Moreover, following experiments to test an 
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expanded range of signatures and improvement / understanding of the performance of the 3D 
signature, data evaluation will allow the generation of more standardized cut offs for each 
signature and a determination of the number of positive signatures in the multiplex required to 
actually call a sample positive.  This further work will likely generate a robust and reliable FMD 
DIVA assay for validation and use in the field.   
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Figure 1.  Schematic of bead-based, multiplexed non-structural protein antibody assay.  A 
peptide or non-structural protein is covalently conjugated to a Luminex™ bead.  The peptide or 
recombinant protein captures antibodies to non-structural proteins in serum samples from cattle 
infected with FMDV.  The captured antibodies are subsequently detected by a secondary 
biotinylated detector antibody, followed by a fluorescent reporter molecule.  The complex is 
analyzed in a flow cytometer.  The beads are interrogated one at a time. A classification laser 
(635 nm) excites the dye molecules inside the bead and classifies the bead to its unique bead set.  
A reporter laser (532 nm) excites bound fluorescent reporter and quantifies the assay at the bead 
surface—only those beads labeled with a reporter molecule will fluoresce in the yellow, and the 
signal is proportional to captured antibody concentration. 
 
Figure 2.  Responses of each signature in multiplexed assay to challenge with sera from 104 
FMD naïve cattle to illustrate expected variation in a naïve population.  Responses of assay 
beads are reported as median fluorescence intensity (MFI) of the assay bead normalized using 
the MFI of the negative control (NC) BSA-coated bead in each sample.  All signatures are on 
shown on the same scale for visual comparison.  Positive bars indicate a normalized MFI value 
above cut off.  Cuts offs are determined from this naïve population to give 95-97 % specificity.  
Negative bars indicate a normalized MFI value below cut off.  (a) 3A peptide, 97 % specificity 
cut off.  (b) 3B peptide, 95 % cut off.  (c) 3D peptide, 97 % cut off.  (d) 3ABC protein 95 % cut 
off. 
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Figure 3.  Responses of each signature in multiplexed assay to challenge with sera from 94 
vaccinated cattle to illustrate expected response of a vaccinated population.  Black bars are 
responses to sera from cattle 14 dpv; gray bars are responses to sera from cattle 21 dpv.  Vaccine 
strains are listed in the supplemental material.  Responses of assay beads are reported as median 
fluorescence intensity (MFI) of the assay bead normalized using the MFI of the negative control 
(NC) BSA-coated bead in each sample.  All signatures are on shown on the same scale for visual 
comparison.  Positive bars indicate a normalized MFI value above cut off.  Cuts offs are 
determined from naïve population to give 95-97 % specificity.  Negative bars indicate a 
normalized MFI value below cut off.  (a) 3A peptide, 97 % specificity cut off.  (b) 3B peptide, 95 
% cut off.  (c) 3D peptide, 97 % cut off.  (d) 3ABC protein 95 % cut off. 
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TABLE 1.  Origin of bovine serum panel to test relative sensitivity of nsp antibody assay assays 
(13, 14, 38). 
Sample 
Identifier 
Vaccination 
strain 
Challenge 
serotypea
Challenge 
methoda
Clinical 
signs 
dpc sera 
taken 
Vaccinated, carrier cattle 
UV9 O Manisa O UKG Contact  174 
UV10 O Manisa O UKG Contact  174 
UV11 O Manisa O UKG Contact  174 
UV13 O Manisa O UKG Contact  174 
UV17 O Manisa O UKG Contact  174 
UV19 O Manisa O UKG Contact  174 
UY83 O Manisa O UKG Contact  107 
UY90 O Manisa O UKG Contact  106 
UZ58 A Iran 96 A Iran 96 Contact  32 
UZ59 A Iran 96 A Iran 96 Contact  32 
UZ60 A Iran 96 A Iran 96 Contact  32 
UZ62 A Iran 96 A Iran 96 Contact  32 
VE63 Asia 1 Shamir Asia 1 Shamir Innoculation  42 
VE64 Asia 1 Shamir Asia 1 Shamir Innoculation  42 
VE65 Asia 1 Shamir Asia 1 Shamir Innoculation Yes 42 
VE66 Asia 1 Shamir Asia 1 Shamir Innoculation  42 
VE67 Asia 1 Shamir Asia 1 Shamir Innoculation Yes 42 
VL83 SAT2 3218 SAT2 Eritrea Innoculation  36 
 30
VL89 SAT2 3218 SAT2 Eritrea Innoculation Yes 36 
VL90 SAT2 3218 SAT2 Eritrea Innoculation  37 
Unvaccinated, carrier cattle 
UZ68 n/a A Iran 96 Innoculation Yes 33 
UZ69 n/a A Iran 96 Innoculation Yes 33 
UY95 n/a O UKG Contact Yes 107 
UY96 n/a O UKG Contact Yes 107 
UV26 n/a O UKG Contact Yes 174 
VH44 n/a O UKG Contact Yes 40 
VH45 n/a O UKG Contact Yes 40 
Vaccinated, non-carrier cattle 
VE73  Asia 1 Shamir Innoculation  43 
VE71  Asia 1 Shamir Innoculation  43 
UZ54  A Iran 96 Innoculation Yes 32 
UY79 O Manisa O UKG Contact  106 
Unvaccinated, non-carrier cattle 
VE60 n/a Asia 1 Shamir Innoculation Yes 42 
VE62 n/a Asia 1 Shamir Innoculation Yes 42 
UY94 n/a O UKG Contact Yes 107 
UV23 n/a UKG 34/01 Contact Yes 37 
UV24 n/a O UKG Contact Yes 174 
a Cattle were challenged 21 dpv. 
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TABLE 2.  Normalized MFI values for each signature in multiplexed non structural protein 
antibody assay in response to bovine serum panel and comparison with results of Cedi® test 
(38). 
Sample 
Identifier 
Normalized 
MFIa
3A 
Normalized 
MFIa
3B 
Normalized 
MFIa
3D 
Normalized 
MFIa
3ABC 
Qualitative 
result for 
Cedi® testb
Cut offc 14 14 43 10 n/a 
NSSd 3 4 6 3 n/a 
Vaccinated, carrier cattle 
UV9 10 14 11 13 + 
UV10 8 20 11 12 + 
UV11 11 13 16 16 + 
UV13 17 13 11 28 + 
UV17 9 11 5 12 + 
UV19 19 12 13 26 + 
UY83 4 7 4 8 + 
UY90 14 22 11 19 + 
UZ58 52 32 11 72 + 
UZ59 15 15 16 26 - 
UZ60 30 29 16 53 + 
UZ62 21 15 21 28 - 
VE63 35 7 16 36 + 
VE64 94 26 12 103 + 
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VE65 102 56 104 129 + 
VE66 130 69 19 126 + 
VE67 344 69 104 342 + 
VL83 70 127 147 136 + 
VL89 91 56 124 99 + 
VL90 85 20 18 91 + 
Unvaccinated, carrier cattle 
UZ68 138 55 72 174 + 
UZ69 205 192 208 265 + 
UY95 41 49 49 100 + 
UY96 13 12 4 20 + 
UV26 24 16 28 36 + 
VH44 29 32 61 53 + 
VH45 14 16 9 38 + 
Vaccinated, non-carrier cattle 
VE73 21 31 18 91 + 
VE71 207 76 41 261 + 
UZ54 49 74 11 109 +/- 
UY79 9 7 20 10 + 
Unvaccinated, non-carrier cattle 
VE60 220 61 132 228 + 
VE62 144 95 81 221 + 
UY94 20 13 5 27 + 
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UV23 127 69 126 181 + 
UV24 45 15 10 42 + 
a  Normalized Median Fluorescence Intensity (MFI):  Assay bead MFI / Negative control (NC) 
MFI.  Data are an average of two experiments, three repeats for each sample in each experiment.  
SD’s for all values are listed in the supplemental material and are typically ~10 % of value.  
Bolded, shaded values are above the cut off and therefore positive for antibodies against the non-
structural proteins.  
b  Data taken from Parida et al (38); Cedi® test is a 3ABC ELISA; + positive in all test, - 
negative in all tests, +/- some tests positive and some tests negative. 
c  Cuts offs are determined from naïve population to give 95-97 % specificity:  3A peptide, 97 %; 
3B peptide, 95 %; 3D peptide, 97%; 3ABC protein 95 %. 
d  NSS: Normal Sigma Serum.  Assay response to normal serum commercially available from 
Sigma; average of 95 repeats as an untreated sera standard control. 
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TABLE 3.  Comparison of normalized MFI values for each signature in multiplexed DIVA in 
response to bovine serum panel when sera are heat inactivated and untreated. 
Sample 
Identifier 
Normalized MFIa
3A 
Normalized MFIa
3B 
Normalized MFIa
3D 
Normalized MFIa
3ABC 
 HIb Δc HIb Δc HIb Δc HIb Δc
Cut offd 14 n/a 14 n/a 43 n/a 10 n/a 
NSSe 3 n/a 4 n/a 6 n/a 3 n/a 
Vaccinated, carrier cattle 
UV9 13 +3 18 +4 14 +4 14 +1 
UV10 8 0 17 -3 12 -1 10 -2 
UV11 12 +1 13 0 19 +3 15 -1 
UV13 11 -6 10 -3 10 -1 20 -8 
UV17 9 0 12 -1 7 -2 11 -1 
UV19 20 -1 11 -1 15 -2 25 -1 
UY83 4 0 7 0 5 +1 7 -1 
UY90 12 -2 20 -2 11 0 18 -1 
UZ58 47 -5 30 -2 11 0 64 -8 
UZ59 14 -1 14 -1 18 +2 25 -1 
UZ60 31 +1 29 0 18 +2 54 +1 
UZ62 18 -3 11 -4 19 -3 21 -7 
VE63 37 +2 5 -2 13 -3 30 -6 
VE64 89 -5 21 -5 12 0 93 -10 
VE65 96 -6 49 -7 89 -15 116 -13 
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VE66 123 -7 62 -7 19 0 124 -2 
VE67 409 +65 77 +8 126 +22 427 +85 
VL83 55 -15 93 -34 103 -44 105 -31 
VL89 76 -15 51 -5 113 -11 80 -19 
VL90 67 -18 17 -3 17 -1 70 -21 
Unvaccinated, carrier cattle 
UZ68 103 -35 41 -14 61 -11 140 -34 
UZ69 227 +22 209 +17 256 +28 296 +31 
UY95 46 +5 51 +2 64 +15 100 0 
UY96 10 -3 10 -2 4 0 16 -4 
UV26 17 -7 12 -4 22 -6 24 -12 
VH44 25 -4 24 -8 47 -14 41 -12 
VH45 12 -2 13 -3 8 -1 30 -8 
Vaccinated, non-carrier cattle 
VE73 12 -9 10 -21 16 -2 11 -80 
VE71 109 -98 42 -34 31 -10 135 -126 
UZ54 37 -12 51 -23 9 -2 65 -44 
UY79 6 -3 5 -2 15 -5 7 -3 
Unvaccinated, non-carrier cattle 
VE60 140 -80 39 -22 87 -45 146 -82 
VE62 73 -71 46 -49 45 -36 112 -109 
UY94 17 -3 11 -2 5 0 25 -2 
UV23 62 -65 34 -35 42 -84 89 -92 
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UV24 31 -34 9 -6 9 -1 33 -9 
a  Normalized Median Fluorescence Intensity (MFI):  Assay bead MFI / Negative control (NC) 
MFI.  Data are an average of three repeats for each sample.  SD’s for all values are listed in the 
supplemental material and are typically ~40 % of value.  Bolded, shaded values are above the cut 
off and therefore positive for antibodies against the non-structural proteins.  Boxed values 
indicate a change in status (positive to negative) after the sera are heat treated when compared to 
the untreated sera. 
b  HI: Heat inactivated. 
c  Δ: Response with untreated sera (reported in Table 2) minus response with heat inactivated 
sera.  A negative result indicates response with heat inactivated sera is lower. 
d  Cuts offs are determined from naïve population to give 95-97 % specificity:  3A peptide, 97 % 
; 3B peptide, 95 %; 3D peptide, 97 % ; 3ABC protein 95 %.  Cut offs were determined from 
analysis of untreated sera. 
e  NSS: Normal Sigma Serum.  Assay response to normal serum commercially available from 
Sigma; average of 95 repeats as an untreated sera standard control. 
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TABLE 4.  Normalized MFI values for each signature in multiplexed non structural protein 
antibody assay in response to serum samples taken over a vaccination / challenge experiments 
with the O serotype — Vaccination O1 Manisa, Challenge OUKG 34/2001 and comparing 28 dpi 
with results of the Cedi® test (14, 36, 37). 
 Normalized MFIa
3A 
Normalized MFIa
3B 
Normalized MFIa
3D 
Normalized MFIa
3ABC 
Sample 
Identifierb
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
28d
dpc 
Vaccinated, non-carrier cattle 
UV3 7 7 7 x 8 10 9 x 12 12 12 x 3 3 4 x - 
UV4 5 4 x 3 6 6 x 3 14 12 x 6 2 3 x 2 - 
UV6 12 7 13 6 6 5 8 6 13 9 18 11 10 6 8 5 - 
UV7 12 7 6 6 16 9 5 4 34 25 23 21 6 5 4 4 - 
UV8 3 5 5 6 5 8 7 8 18 19 18 15 2 3 3 3 - 
UV12 21 83 20 18 6 34 6 4 26 58 16 13 9 25 7 8 - 
UV15 9 9 13 21 8 5 6 6 11 10 11 10 5 6 7 13 - 
UV16 13 8 7 9 10 8 7 8 12 10 9 13 4 3 2 6 - 
UV18 8 6 6 4 13 9 11 8 22 14 14 13 5 5 4 4 - 
UV20 6 6 6 12 13 9 6 10 19 18 17 40 4 4 3 11 - 
UV21 6 2 1 1 8 3 1 1 16 8 2 2 3 1 0 1 - 
Vaccinated, carrier cattle 
UV2 7 6 7 4 6 5 6 3 12 10 13 6 4 3 5 3 - 
UV5 6 7 5 9 4 5 3 6 10 11 9 9 3 4 3 9 + 
UV9 12 7 5 23 13 10 5 16 20 15 11 15 6 5 3 26 + 
UV10 10 8 8 12 7 7 4 11 18 18 17 17 5 5 5 15 + 
UV11 8 8 6 22 9 8 5 11 16 16 12 19 4 4 3 26 + 
UV13 5 6 6 23 9 6 5 12 11 10 11 17 5 6 7 30 + 
UV14 8 7 6 9 10 8 6 11 15 11 11 13 4 4 3 6 - 
UV17 3 2 3 7 2 2 2 6 3 3 4 4 3 2 2 10 + 
UV19 x 6 7 22 x 7 9 16 x 12 14 16 x 4 3 23 + 
Unvaccinated, control cattle 
UV22 6 7 5 123 8 9 7 51 16 16 13 98 3 4 3 145 + 
UV23 6 5 6 85 8 6 6 40 60 38 33 79 3 4 3 105 + 
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UV24 9 6 6 262 12 10 9 89 10 9 9 58 5 4 4 219 + 
UV25 8 6 7 155 6 5 5 31 14 10 12 15 5 4 4 162 + 
UV26 9 8 7 90 7 6 5 53 43 26 20 97 5 6 5 116 + 
a  Normalized Median Fluorescence Intensity (MFI):  Assay bead MFI / Negative control (NC) 
MFI.  Data are an average of three repeats for each sample.  SD’s for all values are listed in the 
supplemental material and are typically ~10 % of value.  Bolded, shaded values are above the cut 
off and therefore positive for antibodies against the non-structural protein signature.  Cuts offs 
are listed in Tables 2 and 3 and are determined from naïve population to give 95-97 % 
specificity:  3A peptide, 97 %; 3B peptide, 95 %; 3D peptide, 97 %; 3ABC protein 95 %.  Cut 
offs were determined from analysis of untreated sera. 
b  Samples were derived from vaccination / challenge experiments and taken from cattle 0 dpv, 
14 dpv, 21 dpv/0 dpc, and 28 dpc.  Full experimental details of the vaccination / challenge 
experiments and classification of cattle as carriers / non-carriers has been previously reported 
(14). 
c  21 dpv = 0 dpc. 
d  28 dpc quantitative results of the Cedi® test, a 3ABC ELISA (14). 
x :  Sample missing; Samples UV3, 28 dpc; UV4, 21 dpv and UV19, 0 dpv were missing. 
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TABLE 5.  Normalized MFI values for each signature in multiplexed non structural protein 
antibody assay in response to serum samples taken over a vaccination / challenge experiments 
with O serotype — Vaccination O1 Manisa, Challenge OUKG 34/2001.  The vaccination dose 
was increased ten-fold compared to experiments used to generate serum samples reported in 
Table 4 and comparing 28 dpi with results of the Cedi® test (13, 36, 37). 
 Normalized MFIa
3A 
Normalized MFIa
3B 
Normalized MFIa
3D 
Normalized MFIa
3ABC 
Sample 
Identifierb
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
0 
dpv 
14 
dpv 
21c 
dpv 
28 
dpc 
28d
dpc 
Vaccinated, non-carrier cattle 
UY72 6 11 7 23 4 10 6 26 9 12 9 12 3 5 4 17 + 
UY73 1 1 2 4 1 2 2 4 2 14 19 21 1 1 1 3 - 
UY74 1 1 2 6 1 1 1 4 6 14 14 26 1 4 2 5 - 
UY77 5 7 5 6 5 7 5 8 23 73 48 47 3 4 3 3 - 
UY78 5 7 5 5 6 9 6 7 9 14 9 9 3 3 2 3 - 
UY79 5 5 4 3 5 6 4 4 17 32 25 14 3 2 2 5 + 
UY80 5 5 6 34 5 7 5 6 9 12 12 11 3 3 3 30 - 
UY81 17 36 21 15 5 8 4 4 14 37 27 19 20 42 21 16 - 
UY82 3 3 4 5 5 5 6 6 24 36 28 24 2 3 3 3 - 
UY83 1 0 0 2 1 1 0 2 1 1 1 3 1 0 0 2 - 
UY84 7 10 7 6 13 18 9 10 8 11 7 7 6 7 5 4 - 
UY85 10 9 3 4 7 8 4 5 10 10 3 5 5 5 2 2 - 
UY86 7 9 8 10 3 5 5 9 3 4 6 16 6 8 6 9 - 
UY87 12 10 11 21 8 6 6 14 96 58 64 40 14 9 10 27 + 
UY88 6 7 7 8 10 9 10 11 15 11 11 13 4 4 4 4 - 
UY89 6 7 6 7 9 11 9 9 13 13 11 11 4 8 6 4 - 
UY91 3 5 3 6 3 4 4 5 34 65 58 41 2 2 2 3 - 
UY92 6 5 8 1 6 5 6 0 11 7 8 1 4 3 7 0 - 
Vaccinated, carrier cattle 
UY76 2 3 4 53 3 5 5 11 4 6 7 13 2 2 2 53 + 
UY90 6 8 6 15 4 5 4 11 5 6 7 13 3 5 4 16 + 
Unvaccinated, control cattle 
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UY93 14 7 7 115 13 11 9 77 14 8 8 48 7 4 5 193 + 
UY94 1 2 3 138 5 14 11 51 3 5 5 13 1 2 2 163 + 
UV95 15 16 11 81 10 8 8 48 21 15 14 85 14 9 6 124 + 
UY96 5 2 2 86 7 3 4 47 9 4 4 20 3 1 2 197 + 
UY97 8 8 7 146 11 9 8 51 10 9 10 63 5 5 5 158 + 
a  Normalized Median Fluorescence Intensity (MFI):  Assay bead MFI / Negative control (NC) 
MFI.  Data are an average of three repeats for each sample.  SD’s for all values are listed in the 
supplemental material and are typically ~10 % of value.  Bolded, shaded values are above the cut 
off and therefore positive for antibodies against the non-structural protein signature.  Cuts offs 
are listed in Tables 2 and 3 and are determined from naïve population to give 95-97 % 
specificity:  3A peptide, 97 %; 3B peptide, 95 %; 3D peptide, 97 %;  3ABC protein 95 %.  Cut 
offs were determined from analysis of untreated sera. 
b  Samples were derived from vaccination / challenge experiments and taken fro cattle 0 dpv, 14 
dpv, 21 dpv/0 dpc, and 28 dpc.  Vaccines were administered at ten times the dosage used to 
generate serum samples reported in Table 4.  Full experimental details of the vaccination / 
challenge experiments and classification of cattle as carriers / non-carriers has been previously 
reported (13). 
c  21 dpv = 0 dpc. 
d  28 dpc quantitative results of the Cedi® test, a 3ABC ELISA (13). 
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